ReviewGenes2016
Telomerase Activation in Hematological Malignancies.
Review in Genes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- THOR methylation as a pan-cancer mechanism ofFrontiers in oncology · 2026Review
- Exploiting the Achilles' heel of cancer through a structure-based drug-repurposing approach and experimental validation of top drugs using the TRAP assay.Molecular diversity · 2025Article
- Review
- Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity.Cancer immunology, immunotherapy : CII · 2025Article
- Associations betweenBiomedicines · 2024Article
- Telomere length and hTERT genetic variants as potential prognostic markers in multiple myeloma.Scientific reports · 2023Article
- Spotlight onGenes · 2023Article
- Exploring hTERT promoter methylation in cutaneous T-cell lymphomas.Molecular oncology · 2022Article
- Methylation of Subtelomeric Chromatin Modifies the Expression of the lncRNA TERRA, Disturbing Telomere Homeostasis.International journal of molecular sciences · 2022Article
- TERT rs2853669 as a predictor for overall survival in patients with acute myeloid leukaemia.Archives of medical science : AMS · 2022Article
- Correlation ofCell journal · 2021Article
- Myelodysplastic syndromes in a pediatric patient with Cri du Chat syndrome with a ring chromosome 5.International journal of hematology · 2020Article
- Variability within the humanOncoTargets and therapy · 2019Article
- Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma.Journal of translational medicine · 2018Article
- Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.International journal of molecular sciences · 2018Article
- Telomere Length and Hematological Disorders: A Review.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomerase expression and telomere maintenance are critical for cell proliferation and survival, and they play important roles in development and cancer, including hematological malignancies. Transcriptional regulation of the rate-limiting subunit of human telomerase reverse transcriptase gen (hTERT) is a complex process, and unveiling the mechanisms behind its reactivation is an important step for the development of diagnostic and therapeutic applications. Here, we review the main mechanisms of telomerase activation and the associated hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.